Amy B. Heimberger

The University of Texas MD Anderson Cancer

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• GENE-57 - COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA

  Friday, November 22
  4:15 PM – 4:25 PM

• RTHP-18 - Prospective Phase II Randomized Trial Comparing Proton Therapy vs. Photon IMRT for Newly Diagnosed GBM: Secondary Analysis Comparison of Gender and Neutrophil-Lymphocyte Ratio (NLR) in GBM Outcomes

  Friday, November 22
  7:30 PM – 9:30 PM

• IMMU-42 - CD8+ T-cells mediate immunoediting, and influence genotype, tumor oncogenic pathways and microenvironment during progression of murine gliomas

  Friday, November 22
  7:30 PM – 9:30 PM

• IMMU-10 - Establishing Effective Models for Immunotherapy in GBM

  Friday, November 22
  7:30 PM – 9:30 PM

• PATH-55 - Mutations of H3.3 and H3.1 in a large cohort of gliomas

  Friday, November 22
  8:06 PM – 8:10 PM

• TMIC-60 - Comprehensive spatial characterization of immune cells in the CNS brain tumor microenvironment

  Friday, November 22
  8:18 PM – 8:22 PM

• NIMG-03 - Prospective Phase II Randomized Trial Comparing Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical and Radiological Assessment

  Saturday, November 23
  3:45 PM – 3:55 PM

• GENE-41 - Understanding the differences in adolescent and young adult (AYA) gliomas and older adult (OA) gliomas based on functional molecular subgroups

  Sunday, November 24
  9:50 AM – 9:55 AM